To include your compound in the COVID-19 Resource Center, submit it here.

Xgeva denosumab regulatory update

The European Commission approved Xgeva denosumab from Amgen to prevent skeletal-related events in adults with bone metastases from

Read the full 186 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE